A phase 1/2 investigator-initiated trial to determine safety, efficacy, and key translational data of CNTY-101 in systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathy, and diffuse cutaneous systemic sclerosis
Latest Information Update: 27 Jan 2025
Price :
$35 *
At a glance
- Drugs CNTY-101 (Primary)
- Indications Diffuse scleroderma; Lupus nephritis; Myositis; Systemic lupus erythematosus
- Focus Adverse reactions; Therapeutic Use
- Acronyms CARAMEL Trial
- 27 Jan 2025 New trial record
- 21 Jan 2025 According to a Century Therapeutics media release, the CARAMEL trial with Century is intended to commence in mid-2025 following CTA approval.
- 21 Jan 2025 According to a Century Therapeutics media release, company has entered into an agreement for an investigator-initiated Phase 1/2 trial by Professors Georg Schett and Andreas Mackensen of CNTY-101 in patients with B-cell mediated autoimmune diseases. The IIT, which is sponsored by the Friedrich-Alexander University Erlangen-Nurnberg, , represents the first evaluation by the internationally recognized Schett/Mackensen group.